Products

Rcnet 25mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Oncology Care Rcnet 25mg Capsule is a high-potency oral antineoplastic agent featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Rcnet is a cornerstone in modern precision oncology. Manufactured by RPG Life Sciences, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 25mg strength is a vital dosage for precise titration, allowing oncologists to tailor the treatment regimen to the patient’s specific clinical response and tolerability. Therapeutic Indications and Global Clinical Usage Rcnet 25mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Used as a primary treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Rcnet 25mg Works Rcnet employs a dual-action strategy to combat tumor progression by targeting various receptors on the surface of cancer cells and blood vessel cells: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Rcnet helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Rcnet 25mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen: Often used in a “4 weeks on, 2 weeks off“ cycle or as a continuous daily dose depending on the specific cancer type. Precision Titration: The 25mg strength is essential for dose modifications required to manage side effects while maintaining therapeutic efficacy. Consistency: It can be taken with or without food, but taking it at a consistent time each day is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Treatment with targeted therapies like Rcnet 25mg requires consistent medical oversight: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect. Skin and Hair Changes: Patients may experience skin yellowing (discoloration), hair depigmentation, or hand-foot syndrome during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutekast 50 mg Capsule 28's (Sunitinib): High-Potency Targeted Therapy for Advanced Oncology. Sutekast 50 mg Capsule 28's is a maximum-strength, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. As a sophisticated multi-targeted receptor tyrosine kinase (RTK) inhibitor, the 50 mg dosage is the standard therapeutic strength used to achieve profound tumor suppression in aggressive cancers. Manufactured by Aprazer Healthcare, Sutekast is engineered to disrupt the signaling pathways that allow cancer cells to grow, divide, and develop the blood supply necessary for tumor survival. The 28-capsule pack is specifically designed to align with the standard 4-week treatment cycle. Therapeutic Indications and Clinical Usage Sutekast 50 mg is a cornerstone in international oncology protocols for: Advanced Renal Cell Carcinoma (RCC): Used as a first-line treatment for metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients with GIST after disease progression on or intolerance to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: Used in high-risk patients to prevent the recurrence of RCC following a nephrectomy (kidney removal surgery). Mechanism of Action: How Sutekast 50mg Works Anti-Angiogenesis: It inhibits Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels. Signal Transduction Blockade: It targets various other tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled proliferation of malignant cells. Metastasis Inhibition: By disrupting these vital biological pathways, Sutekast helps limit the cancer's ability to invade surrounding tissues or spread to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical clinical schedule involves 50 mg taken once daily for 4 weeks (one full pack of 28's), followed by a 2-week rest period (the 4/2 cycle). Method of Administration: Capsules must be swallowed whole with water. They should not be crushed, opened, or chewed. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Dose Adjustments: Based on individual patient tolerability and clinical response, oncologists may modify the dosage. Safety Profile and Professional Monitoring High-strength TKI therapy requires vigilant medical supervision to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are mandatory, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Hypothyroidism is a common side effect; patients require regular thyroid-stimulating hormone (TSH) testing. Skin and Hair Changes: Patients may experience skin discoloration (yellowing), hair depigmentation, or hand-foot syndrome. Liver and Heart Health: Periodic monitoring of liver enzymes and LVEF (heart function) is standard practice. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep capsules in the original container (28's pack) to protect them from moisture and light. Safety: Caregivers should handle the medication with care, avoid contact with broken capsules, and keep it out of reach of children. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Nitnib 25mg Capsule is a high-potency oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Nitnib is a cornerstone in modern precision oncology. Manufactured by Sun Pharma, a global leader in high-quality pharmaceuticals, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 25 mg strength is a critical dosage for precise titration, allowing oncologists to tailor the treatment regimen to the patient’s specific clinical response and tolerability. Therapeutic Indications and Global Clinical Usage Nitnib 25 mg is a preferred therapeutic agent in international oncology protocols for: Advanced Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients with GIST after disease progression on or intolerance to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Nitnib 25mg Works Nitnib 25 mg exerts its clinical effect by simultaneously targeting multiple receptors involved in tumor growth: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Signal Transduction Blockade: It targets various other tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital biological pathways, Nitnib helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Nitnib 25 mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical clinical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg, often achieved by combining 25mg and 12.5mg strengths) without a rest period. Flexibility: The 25mg strength is essential for dose modifications required to manage side effects while maintaining therapeutic efficacy. Consistency: It can be taken with or without food, but taking it at a consistent time each day is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Treatment with targeted therapies like Nitnib 25mg requires consistent medical oversight: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels (TSH) checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration), hair depigmentation, or hand-foot syndrome during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard clinical practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sunisam 25mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Oncology. Sunisam 25mg Capsule is a high-potency oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. As a sophisticated multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sunisam is a cornerstone in modern precision medicine. Manufactured by Samarth Life Sciences, it is designed to disrupt the life cycle of cancer cells by blocking specific signaling pathways that promote tumor growth, cellular division, and vascularization. The 25 mg strength is a critical dosage for precise titration, ensuring patients receive the optimal therapeutic benefit while managing systemic tolerability. Therapeutic Indications and Clinical Usage Sunisam 25 mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Advanced Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment for RCC: In specific high-risk scenarios, it is utilized to reduce the risk of cancer recurrence following a nephrectomy (surgical removal of the kidney). Mechanism of Action: How Sunisam 25mg Works Sunisam employs a dual-action strategy to combat tumor progression by targeting various receptors involved in cancer development: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sunisam helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sunisam 25 mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): Typically involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg, often achieved using combination strengths) without a rest period. Flexibility: The 25 mg strength is essential for dose modifications required to manage side effects while maintaining therapeutic efficacy. Consistency: It can be taken with or without food, but taking it at a consistent time each day is recommended. Safety Profile and Professional Monitoring Treatment with Sunisam 25 mg requires consistent medical oversight to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels (TSH) checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration), hair depigmentation, or hand-foot syndrome. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard clinical practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the prescribed patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutekast 25 mg Capsule (Sunitinib): Targeted Multi-Kinase Inhibition for Precision Oncology. Sutekast 25mg Capsule is a high-efficacy, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. As a sophisticated multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutekast represents a critical advancement in the treatment of various aggressive malignancies. Manufactured by Aprazer Healthcare, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 25 mg strength is a vital dosage for precise titration, ensuring that patients receive the optimal therapeutic benefit while maintaining systemic tolerability. Therapeutic Indications and Global Clinical Usage Sutekast 25 mg is a cornerstone in international oncology protocols for: Advanced Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients with GIST after disease progression on or intolerance to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Sutekast 25mg Works Sutekast 25 mg exerts its clinical effect by simultaneously targeting multiple receptors involved in tumor growth: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Signal Transduction Blockade: It targets various other tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutekast helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sutekast 25 mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical clinical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg, often achieved by combining 25 mg and 12.5 mg strengths) without a rest period. Consistency: It can be taken with or without food, but taking it at a consistent time each day is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Treatment with targeted therapies like Sutekast 25 mg requires consistent medical oversight: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels (TSH) checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration), hair depigmentation, or hand-foot syndrome during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard clinical practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the prescribed patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutent 25mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Malignancies Sutent 25mg Capsule is a potent oral antineoplastic medication containing the active pharmaceutical ingredient Sunitinib. As a breakthrough in targeted cancer therapy, Sutent is classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor. Manufactured by Pfizer, it is designed to inhibit the growth, signaling, and blood supply of malignant cells. The 25mg strength is a critical dosage for precise titration, allowing oncologists to tailor the treatment regimen to the patient’s specific clinical response and tolerability. Therapeutic Indications and Clinical Usage Sutent 25mg is a cornerstone in international oncology protocols for several aggressive conditions: Advanced Renal Cell Carcinoma (RCC): Indicated as a primary first-line treatment for metastatic kidney cancer to prolong progression-free survival and improve patient outcomes. Gastrointestinal Stromal Tumor (GIST): Specifically prescribed for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Used for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment for RCC: In specific high-risk scenarios, Sutent is utilized to reduce the risk of cancer recurrence following a nephrectomy (surgical removal of the kidney). Mechanism of Action: How Sutent 25mg Works Sutent employs a sophisticated “multi-kinase“ approach to disrupt tumor progression on several fronts: Anti-Angiogenesis: It targets Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). By blocking these signals, Sutent prevents the tumor from developing the new blood vessels it needs to grow. Inhibition of Proliferation: It inhibits other receptor tyrosine kinases (such as KIT, FLT3, and RET) that are responsible for the rapid and uncontrolled division of cancer cells. Metastasis Suppression: By interfering with these critical signaling pathways, the medication helps limit the cancer's ability to migrate and invade other parts of the body. Dosage and Administration Guidelines Method of Administration: Sutent 25mg capsules must be swallowed whole with water; do not open, crush, or chew. Food Interaction: It can be taken with or without food, but consistency in timing is recommended to maintain steady-state plasma concentrations. Standard Regimen (RCC/GIST): Often follows a “4 weeks on, 2 weeks off“ schedule (the 4/2 cycle). Continuous Regimen (pNET): Generally administered as a continuous daily dose (usually 37.5 mg, often achieved using 25mg and 12.5 mg combinations). Precise Titration: The 25mg strength is essential for dose modifications required to manage side effects while maintaining therapeutic efficacy. Safety Profile and Professional Monitoring Cardiovascular Health: Regular blood pressure checks are essential, as Sunitinib frequently causes hypertension. Thyroid Function: Periodic monitoring for hypothyroidism is required, as this is a common side effect of TKI therapy. Hematological Stability: Periodic blood tests (CBC) to check for neutropenia or thrombocytopenia. Dermatological Effects: Potential skin discoloration (yellowing), hair color changes, or hand-foot syndrome (redness/blistering on palms and soles). Organ Function: Regular testing of liver enzymes and heart function (LVEF) is standard clinical practice. Storage and Handling Instructions Temperature: Store at room temperature, between 20°C and 25°C. Original Packaging: Keep capsules in the original container to protect them from light and moisture. Safety: Ensure the medication is kept out of reach of children and handled only by the prescribed patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutib 50mg Capsule (Sunitinib): High-Potency Targeted Therapy for Advanced Oncology. Sutib 50mg Capsule is a maximum-strength, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. As a sophisticated multi-targeted receptor tyrosine kinase (RTK) inhibitor, the 50 mg dosage is the standard therapeutic strength used to achieve profound tumor suppression in aggressive cancers. Manufactured by Zydus Lifesciences, a global leader in high-quality pharmaceuticals, Sutib is engineered to disrupt the signaling pathways that allow cancer cells to grow, divide, and develop the blood supply necessary for tumor survival. Therapeutic Indications and Clinical Usage Sutib 50mg is a cornerstone in international oncology protocols for: Advanced Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients with GIST after disease progression on or intolerance to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: Used in high-risk patients to prevent the recurrence of RCC following a nephrectomy (kidney removal surgery). Mechanism of Action: How Sutib 50mg Works Sutib 50mg exerts its clinical effect by simultaneously targeting multiple receptors involved in tumor growth: Anti-Angiogenesis: It inhibits Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels. Signal Transduction Blockade: It targets various other tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled proliferation of malignant cells. Metastasis Inhibition: By disrupting these vital biological pathways, Sutib helps limit the cancer's ability to invade surrounding tissues or spread to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical clinical schedule involves 50 mg taken once daily for 4 weeks, followed by a 2-week rest period (the 4/2 cycle). Method of Administration: Capsules must be swallowed whole with water. They should not be crushed, opened, or chewed. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Dose Adjustments: Based on individual patient tolerability and clinical response, oncologists may modify the dosage using lower strengths if necessary. Safety Profile and Professional Monitoring High-strength TKI therapy requires vigilant medical supervision to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are mandatory, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Hypothyroidism is a common side effect; patients require regular thyroid-stimulating hormone (TSH) testing. Skin and Hair Changes: Patients may experience skin discoloration (yellowing), hair depigmentation, or hand-foot syndrome. Liver and Heart Health: Periodic monitoring of liver enzymes and LVEF (heart function) is standard practice. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep capsules in the original container to protect them from moisture and light. Safety: Caregivers should handle the medication with care, avoid contact with broken capsules, and keep it out of reach of children. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sunisam 50mg Capsule (Sunitinib): High-Potency Targeted Therapy for Advanced Malignancies Sunisam 50mg Capsule is a high-efficacy oral antineoplastic agent featuring the active pharmaceutical ingredient Sunitinib. As a sophisticated multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sunisam is a cornerstone in modern precision oncology. Manufactured by Samarth Life Sciences, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 50 mg strength is the standard therapeutic dose used to achieve maximum tumor suppression in aggressive malignancies. Therapeutic Indications and Global Clinical Usage Sunisam 50mg is a preferred therapeutic agent in international oncology protocols for: Advanced Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (surgical removal of a kidney). Mechanism of Action: How Sunisam 50mg Works Sunisam employs a dual-action strategy to combat tumor progression by targeting various receptors on the surface of cancer cells and blood vessel cells: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sunisam helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical clinical schedule involves 50 mg taken once daily for 4 weeks, followed by a 2-week rest period (the 4/2 cycle). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg or as adjusted) without a rest period. Administration: Capsules must be swallowed whole with water; do not crush or chew. Consistency: It can be taken with or without food, but taking it at a consistent time each day is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Treatment with high-strength TKIs like Sunisam 50 mg, which requires consistent medical oversight: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration), hair depigmentation, or hand-foot syndrome during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutykine 50mg Capsule (Sunitinib): Targeted Tyrosine Kinase Inhibition for Advanced Oncology Sutykine 50mg Capsule is a high-potency oral antineoplastic medication containing the active ingredient Sunitinib. As a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutykine 50mg is a cornerstone in the treatment of various aggressive malignancies. Manufactured by Intas Pharmaceuticals Ltd., a globally recognized leader in oncology, this medication is designed to disrupt the signaling pathways that allow cancer cells to grow, divide, and develop the blood supply necessary for tumor survival. Therapeutic Indications and Global Clinical Usage Sutykine 50mg is utilized in international oncology protocols for several complex conditions: Renal Cell Carcinoma (RCC): Indicated as a primary first-line treatment for advanced or metastatic kidney cancer to improve progression-free survival. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In specific clinical scenarios, it is used to reduce the risk of cancer returning after kidney surgery (nephrectomy) in high-risk patients. Mechanism of Action: How Sutykine 50mg Works Sutykine 50mg works through a sophisticated multi-pathway approach to inhibit tumor progression: Anti-Angiogenesis: It blocks receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By inhibiting these, it effectively “starves“ the tumor by preventing the formation of new blood vessels. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling processes, Sutykine helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): Typically involves a cycle of 50 mg taken once daily for 4 weeks, followed by a 2-week rest period (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg or as adjusted) without a rest period. Administration: Capsules must be swallowed whole with water; do not crush or chew. Consistency: It can be taken with or without food but should be taken at a consistent time each day to maintain steady-state levels. Dietary Note: Avoid grapefruit and grapefruit juice, as they can interfere with the medication's absorption. Safety Profile and Clinical Monitoring Cardiovascular Health: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Monitoring for hypothyroidism is required, as this is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin discoloration (yellowing), hair depigmentation, or hand-foot syndrome. Liver & Heart Health: Periodic blood tests to check liver enzymes and heart function (LVEF) are standard during treatment. Storage and Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in their original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutinat 50mg Capsule (Sunitinib): High-Potency Targeted Therapy for Advanced Oncology. Sutinat 50mg Capsule is a maximum-strength, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. As a sophisticated multi-targeted receptor tyrosine kinase (RTK) inhibitor, the 50 mg dosage is the standard therapeutic strength used to achieve profound tumor suppression in aggressive cancers. Manufactured by Natco Pharma Ltd., a global leader in high-quality oncology generics, Sutinat is engineered to disrupt the signaling pathways that allow cancer cells to grow, divide, and develop the blood supply necessary for tumor survival. Therapeutic Indications and Clinical Usage Sutinat 50mg is a cornerstone in international oncology protocols for: Advanced Renal Cell Carcinoma (RCC): Used as a first-line treatment for metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients with GIST after disease progression on or intolerance to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: Used in high-risk patients to prevent the recurrence of RCC following a nephrectomy (kidney removal surgery). Mechanism of Action: How Sutinat 50mg Works Sutinat 50mg exerts its clinical effect by simultaneously targeting multiple receptors involved in tumor growth: Anti-Angiogenesis: It inhibits Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels. Signal Transduction Blockade: It targets various other tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled proliferation of malignant cells. Metastasis Inhibition: By disrupting these vital biological pathways, Sutinat helps limit the cancer's ability to invade surrounding tissues or spread to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical clinical schedule involves 50 mg taken once daily for 4 weeks, followed by a 2-week rest period (the 4/2 cycle). Method of Administration: Capsules must be swallowed whole with water. They should not be crushed, opened, or chewed. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Dose Adjustments: Based on individual patient tolerability and clinical response, oncologists may modify the dosage. Safety Profile and Professional Monitoring High-strength TKI therapy requires vigilant medical supervision to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are mandatory, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Hypothyroidism is a common side effect; patients require regular thyroid-stimulating hormone (TSH) testing. Skin and Hair Changes: Patients may experience skin discoloration (yellowing), hair depigmentation, or hand-foot syndrome. Liver and Heart Health: Periodic monitoring of liver enzymes and LVEF (heart function) is standard practice. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep capsules in the original container to protect them from moisture and light. Safety: Caregivers should handle the medication with care, avoid contact with broken capsules, and keep it out of reach of children. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Rcnet 50mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Oncology Care Rcnet 50mg Capsule is a high-potency oral antineoplastic agent featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Rcnet is a cornerstone in modern precision oncology. Manufactured by RPG Life Sciences, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 50 mg strength is the standard therapeutic dose used to achieve maximum tumor suppression in aggressive malignancies. Therapeutic Indications and Global Clinical Usage Rcnet 50mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Rcnet 50mg Works Rcnet employs a dual-action strategy to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Rcnet helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical clinical schedule involves 50 mg taken once daily for 4 weeks, followed by a 2-week rest period (the 4/2 cycle). Administration: Capsules must be swallowed whole with water; do not crush or chew. Consistency: It can be taken with or without food, but taking it at a consistent time each day is recommended to maintain steady-state plasma concentrations. Clinical Monitoring: Dosage may be adjusted by a healthcare professional based on individual patient response and any observed toxicities. Safety Profile and Professional Monitoring Treatment with high-strength TKIs like Rcnet 50mg requires consistent medical oversight: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration), hair depigmentation, or hand-foot syndrome during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Nitnib 50mg Capsule (Sunitinib): High-Potency Targeted Therapy for Advanced Oncology. Nitnib 50mg Capsule is a maximum-strength, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Nitnib is a cornerstone in modern precision oncology. Manufactured by Sun Pharma, a global leader in high-quality pharmaceuticals, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 50mg strength is the standard therapeutic dose used to achieve profound tumor suppression in aggressive cancers. Therapeutic Indications and Global Clinical Usage Nitnib 50 mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Indicated as a first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Used for patients with GIST after disease progression on or intolerance to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Nitnib 50mg Works Nitnib 50 mg exerts its clinical effect by simultaneously targeting multiple receptors involved in tumor growth: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Signal Transduction Blockade: It targets various other tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Nitnib helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical clinical schedule involves 50 mg taken once daily for 4 weeks, followed by a 2-week rest period (the 4/2 cycle). Administration: Capsules must be swallowed whole with water; do not crush or chew. Consistency: It can be taken with or without food, but taking it at a consistent time each day is recommended to maintain steady-state plasma concentrations. Clinical Monitoring: Dosage may be modified by a healthcare professional based on individual patient response and toxicity levels. Safety Profile and Professional Monitoring Treatment with high-strength TKIs like Nitnib 50 mg, which requires consistent medical oversight: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Hypothyroidism is a common side effect; patients require regular thyroid-stimulating hormone (TSH) testing. Skin and Hair Changes: Patients may experience skin yellowing (discoloration), hair depigmentation, or hand-foot syndrome during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383